Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jul;118(6):1421–1428. doi: 10.1111/j.1476-5381.1996.tb15555.x

The relaxant 5-HT receptor in the dog coronary artery smooth muscle: pharmacological resemblance to the cloned 5-ht7 receptor subtype.

J A Terrón 1
PMCID: PMC1909658  PMID: 8832067

Abstract

1. The relaxant effect of 5-hydroxytryptamine (5-HT) in the dog isolated coronary artery deprived of endothelium is mediated by a receptor unrelated to the 5-HT1, 5-HT2, 5-HT3 or 5-HT4 types. Based upon the pharmacological characteristics of this relaxant 5-HT receptor and those reported for the new members of the 5-HT receptor family, the present study explored the possibility that the relaxant 5-HT receptor referred to above, corresponds to the cloned 5-ht7 subtype. Thus, the relaxing and/or blocking effects of several 5-HT receptor drugs as well as some typical and atypical antipsychotic drugs with high affinity for the cloned 5-ht7 receptor in precontracted ring segments were analyzed. 2. 5-HT, 5-carboxamidotryptamine (5-CT) and 5-methoxytryptamine, but not 8-OH-DPAT or sumatriptan, produced concentration-dependent relaxations in endothelium-denuded canine coronary artery rings precontracted with prostaglandin F2a (2 microM). Clozapine (1 microM) produced in some cases a small relaxing effect and antagonized 5-HT- and 5-CT-induced relaxation suggesting a partial agonist effect. In the presence of the 5-HT1D receptor antagonist, GR127935 (100 nM), the rank order of agonist potency was 5-CT > 5-HT > clozapine > or = 5-methoxytryptamine. 8-OH-DPAT and sumatriptan remained inactive as agonists. 3. In GR127935-treated preparations, methiothepin (3 nM) and mianserin (1 microM), as well as the antipsychotics, clozapine (1 microM), pimozide (300 nM), risperidone (3 nM) and spiperone (1 microM), failed to induce a significant relaxation in prostaglandin F2x-precontracted vessels, but produced significant rightward displacements of the concentration-response curves to 5-HT and 5-CT without significantly reducing the Emax. In a final set of experiments with 5-CT, metergoline (100 nM) and mesulergine (300 nM) behaved as competitive antagonists. In contrast, lisuride (3 nM) noncompetitively antagonized 5-CT-induced relaxation. The estimated affinity (apparent pKa values) of the above antagonist drugs for the relaxant 5-HT receptor significantly correlated with their reported affinity at the cloned 5-ht7 receptor. 4. Taken together, the above pharmacological data may suggest that the relaxant 5-HT receptor in the smooth muscle of the canine coronary artery is similar to the cloned 5-ht7 receptor subtype.

Full text

PDF
1421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bard J. A., Zgombick J., Adham N., Vaysse P., Branchek T. A., Weinshank R. L. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422–23426. [PubMed] [Google Scholar]
  2. Cohen B. M., Lipinski J. F. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action. Life Sci. 1986 Dec 29;39(26):2571–2580. doi: 10.1016/0024-3205(86)90111-6. [DOI] [PubMed] [Google Scholar]
  3. Cohen R. A. Contractions of isolated canine coronary arteries resistant to S2-serotonergic blockade. J Pharmacol Exp Ther. 1986 May;237(2):548–552. [PubMed] [Google Scholar]
  4. Cohen R. A., Shepherd J. T., Vanhoutte P. M. Prejunctional and postjunctional actions of endogenous norepinephrine at the sympathetic neuroeffector junction in canine coronary arteries. Circ Res. 1983 Jan;52(1):16–25. doi: 10.1161/01.res.52.1.16. [DOI] [PubMed] [Google Scholar]
  5. Cushing D. J., Baez M., Kursar J. D., Schenck K., Cohen M. L. Serotonin-induced contraction in canine coronary artery and saphenous vein: role of a 5-HT1D-like receptor. Life Sci. 1994;54(22):1671–1680. doi: 10.1016/0024-3205(94)00607-5. [DOI] [PubMed] [Google Scholar]
  6. Cushing D. J., Cohen M. L. Comparison of the serotonin receptors that mediate smooth muscle contraction in canine and porcine coronary artery. J Pharmacol Exp Ther. 1992 Jun;261(3):856–862. [PubMed] [Google Scholar]
  7. Cushing D. J., Cohen M. L. Serotonin-induced relaxation in canine coronary artery smooth muscle. J Pharmacol Exp Ther. 1992 Oct;263(1):123–129. [PubMed] [Google Scholar]
  8. Houston D. S., Vanhoutte P. M. Comparison of serotonergic receptor subtypes on the smooth muscle and endothelium of the canine coronary artery. J Pharmacol Exp Ther. 1988 Jan;244(1):1–10. [PubMed] [Google Scholar]
  9. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R., Humphrey P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994 Jun;46(2):157–203. [PubMed] [Google Scholar]
  10. Hoyer D., Waeber C., Schoeffter P., Palacios J. M., Dravid A. 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization. Naunyn Schmiedebergs Arch Pharmacol. 1989 Mar;339(3):252–258. doi: 10.1007/BF00173573. [DOI] [PubMed] [Google Scholar]
  11. Leysen J. E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J. C., Janssen P. A. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988 Nov;247(2):661–670. [PubMed] [Google Scholar]
  12. Lovenberg T. W., Baron B. M., de Lecea L., Miller J. D., Prosser R. A., Rea M. A., Foye P. E., Racke M., Slone A. L., Siegel B. W. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 1993 Sep;11(3):449–458. doi: 10.1016/0896-6273(93)90149-l. [DOI] [PubMed] [Google Scholar]
  13. Martin G. R. Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther. 1994;62(3):283–324. doi: 10.1016/0163-7258(94)90048-5. [DOI] [PubMed] [Google Scholar]
  14. Meltzer H. Y., Matsubara S., Lee J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989 Oct;251(1):238–246. [PubMed] [Google Scholar]
  15. Monsma F. J., Jr, Shen Y., Ward R. P., Hamblin M. W., Sibley D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320–327. [PubMed] [Google Scholar]
  16. Plassat J. L., Amlaiky N., Hen R. Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229–236. [PubMed] [Google Scholar]
  17. Roth B. L., Ciaranello R. D., Meltzer H. Y. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther. 1992 Mar;260(3):1361–1365. [PubMed] [Google Scholar]
  18. Roth B. L., Craigo S. C., Choudhary M. S., Uluer A., Monsma F. J., Jr, Shen Y., Meltzer H. Y., Sibley D. R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403–1410. [PubMed] [Google Scholar]
  19. Roth B. L., Hamblin M. W., Ciaranello R. D. Developmental regulation of 5-HT2 and 5-HT1c mRNA and receptor levels. Brain Res Dev Brain Res. 1991 Jan 15;58(1):51–58. doi: 10.1016/0165-3806(91)90236-c. [DOI] [PubMed] [Google Scholar]
  20. Ruat M., Traiffort E., Leurs R., Tardivel-Lacombe J., Diaz J., Arrang J. M., Schwartz J. C. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8547–8551. doi: 10.1073/pnas.90.18.8547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shen Y., Monsma F. J., Jr, Metcalf M. A., Jose P. A., Hamblin M. W., Sibley D. R. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200–18204. [PubMed] [Google Scholar]
  22. Sipma H., Duin M., Hoiting B., den Hertog A., Nelemans A. Regulation of histamine- and UTP-induced increases in Ins(1,4,5)P3, Ins (1,3,4,5)P4 and Ca2+ by cyclic AMP in DDT1 MF-2 cells. Br J Pharmacol. 1995 Jan;114(2):383–390. doi: 10.1111/j.1476-5381.1995.tb13238.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tallarida R. J., Cowan A., Adler M. W. pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci. 1979 Aug 20;25(8):637–654. doi: 10.1016/0024-3205(79)90505-8. [DOI] [PubMed] [Google Scholar]
  24. Terrón J. A. GR127935 is a potent antagonist of the 5-HT1-like receptor mediating contraction in the canine coronary artery. Eur J Pharmacol. 1996 Apr 4;300(1-2):109–112. doi: 10.1016/0014-2999(96)00041-6. [DOI] [PubMed] [Google Scholar]
  25. To Z. P., Bonhaus D. W., Eglen R. M., Jakeman L. B. Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain. Br J Pharmacol. 1995 May;115(1):107–116. doi: 10.1111/j.1476-5381.1995.tb16327.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Toda N., Okamura T. Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. J Pharmacol Exp Ther. 1990 May;253(2):676–682. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES